Candel Therapeutics Welcomes Bali Pulendran to Advisory Board
Candel Therapeutics, Inc. (NASDAQ: CADL), a pioneering biopharmaceutical firm focused on innovative immunotherapies for cancer treatment, has recently appointed Dr. Bali Pulendran to its Research Advisory Board (RAB). With a strong background in systems immunology and vaccinology, Dr. Pulendran's expertise will be invaluable as Candel continues to progress its leading candidates, CAN-2409 and CAN-3110, which target various solid tumors.
Dr. Bali Pulendran’s Expertise
Dr. Pulendran brings a wealth of knowledge to the RAB. He is currently the Violetta L. Horton Professor at Stanford University School of Medicine and serves as the Director of the Institute for Immunity, Transplantation and Infection. With an impressive history of research and numerous publications in prestigious journals, his impact on immunology is significant. His work on dendritic cells and their role in immunity establishes a foundational understanding crucial for developing effective cancer therapies.
Impact on Candel’s Development Programs
Reflecting on his new role, Dr. Pulendran stated, “I am honored to join Candel’s Research Advisory Board during this pivotal stage for the Company. Their approach to activating the immune system against cancer resonates with my passion for innovative therapies.” His insights will aid in strengthening Candel’s research and development strategies as they seek to bring CAN-2409 and CAN-3110 to market.
Overview of Candel’s Cancer Treatments
Candel Therapeutics specializes in creating off-the-shelf viral immunotherapies, designed to offer tailored immune responses that assist patients in their fight against cancer. Their lead candidate, CAN-2409, has shown promise in completed phase 2a clinical trials targeting non-small cell lung cancer (NSCLC) and pancreatic ductal adenocarcinoma (PDAC). CAN-2409 has also progressed to a pivotal phase 3 trial for localized prostate cancer, which follows a Special Protocol Assessment by the FDA.
Regulatory Approvals and Designations
Recently, CAN-2409 received Fast Track Designation from the FDA for its potential in specific cancer patient populations. The FDA has also granted Regenerative Medicine Advanced Therapy (RMAT) Designation, which indicates the candidate's potential to address serious conditions and unmet medical needs effectively.
Innovative Approaches with CAN-3110
On the other hand, CAN-3110, derived from Candel’s herpes simplex virus (HSV) platform, is currently undergoing phase 1b trials for recurrent high-grade glioma. This candidate also holds Fast Track and Orphan Drug Designations from the FDA, highlighting its potential in oncology therapies.
The enLIGHTEN™ Discovery Platform
Candel’s enLIGHTEN™ Discovery Platform is a cutting-edge initiative that leverages human biology and advanced analytics. This platform aims to spearhead the development of innovative viral immunotherapies targeted at challenging solid tumors.
Final Thoughts on Candel’s Future
With the addition of Dr. Pulendran to its Research Advisory Board and a clear focus on advancing its clinical trials, Candel Therapeutics is poised to make significant strides in cancer treatment. The integration of such a renowned expert into their advisory team reinforces the Company’s commitment to developing effective therapies that could transform the landscape of cancer care.
Frequently Asked Questions
Who is Bali Pulendran?
Bali Pulendran, Ph.D., is a renowned expert in systems immunology and vaccinology, now serving on Candel’s Research Advisory Board.
What is CAN-2409?
CAN-2409 is Candel’s lead viral immunotherapy candidate currently in clinical trials for various solid tumors, including prostate cancer.
What designations has CAN-2409 received?
CAN-2409 has received Fast Track Designation and Regenerative Medicine Advanced Therapy Designation from the FDA.
What is Candel Therapeutics focused on?
Candel specializes in developing multimodal viral immunotherapies aimed at eliciting a strong anti-tumor immune response to aid cancer patients.
What ongoing trials is CAN-3110 undergoing?
CAN-3110, another Candel candidate, is in a phase 1b clinical trial for recurrent high-grade glioma and has also received Fast Track and Orphan Drug Designations.
